Almorexant

Almorexant (INN, codenamed ACT-078573) is a competitive receptor antagonist of the OX1 and OX2 orexin receptors, being developed by the pharmaceutical company Actelion for the treatment of primary insomnia. It has completed a Phase III clinical trial in November 2009.

Mechanism of action
Almorexant is a competitive, dual OX1 and OX2 receptor antagonist and selectively inhibits the functional consequences of OX1 and OX2 receptor activation, such as intracellular Ca2+ mobilization.

Clinical uses
Almorexant currently is under development for clinical use in primary insomnia.